Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

Core Insights - Kymera Therapeutics is advancing a new class of oral small molecule degrader medicines for immunological diseases, with significant clinical milestones expected in 2026 and beyond [1][2][14] Pipeline Developments - KT-621 is in Phase 2b trials for atopic dermatitis (AD) and asthma, with data expected by mid-2027 and late-2027 respectively [1][10] - KT-579 is set to initiate a Phase 1 clinical trial in healthy volunteers in Q1 2026, with data anticipated in the second half of 2026 [1][8] - The company aims to advance at least one new development candidate towards IND for a first-in-class oral immunology program in 2026 [1][12] Financial Position - Kymera is well-capitalized with $1.6 billion in cash, providing a runway into 2029 [1][2] Clinical Trial Updates - KT-621 has shown promising results in a Phase 1b trial for moderate to severe AD, demonstrating deep STAT6 degradation and significant improvements in clinical endpoints [4] - The BROADEN2 Phase 2b trial for KT-621 includes approximately 200 patients and aims to evaluate efficacy, safety, and tolerability over 16 weeks [10] - The BREADTH Phase 2b trial for KT-621 in eosinophilic asthma will involve around 264 adult patients over 12 weeks [10] Strategic Vision - The company is focused on transforming treatment paradigms for over 140 million patients suffering from Type 2 diseases, aiming to deliver oral medicines that can change the standard of care [2][3]